The monoclonal antibody RBD.01 recognizes SARS-CoV-2 receptor binding domain (RBD) of Spike protein.
SARS-CoV-2 Spike protein is a structural transmembrane glycoprotein comprised of two subunits (S1 and S2), size of 180–200 kDa. It protrudes from the surface of the SARS-CoV-2 virion and is essential for binding to the host cell via host ACE-2 receptor. Spike protein is a main target for neutralizing antibodies and vaccines. Our anti-Spike antibody clone RBD.01 was validated in ELISA (on recombinant Spike and RBD proteins), FACS (on SARS-CoV-2 infected 293T-ACE2 cells) and WB (on recombinant RBD protein), as described in Pribanić Matešić et al. Viruses 2022, 14(2), 443.